title: [Treatment of non-small cell lung cancer].
abstract: Within recent years, the treatment of non-small cell lung cancer has become increasingly heterogeneous and complex. New cytotoxic agents and drugs against molecular targets have been developed. Moreover, new indications for therapy such as maintenance therapy have been explored. In addition, by assessing defined molecular markers, it is possible to identify patients who may likely respond to a given treatment. This approach will continue in the future; thus, it will be possible to characterize patient into subgroups based on molecular, histological, or clinical markers. This review will summarize the current state of the art in the treatment of non-small cell lung cancer.
authors.affiliation: Internistische Onkologie der Thoraxtumoren, Thoraxklinik am Universitätsklinikum Heidelberg, Amalienstrasse 5, Heidelberg, Germany. niels.reinmuth@thoraxklinik-heidelberg.de
authors.forename: N
authors.initials: N
authors.lastname: Reinmuth
authors.forename: D
authors.initials: D
authors.lastname: Heigener
authors.forename: M
authors.initials: M
authors.lastname: Reck
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
references.citation: Chest. 2007 Sep;132(3 Suppl):243S-265S
references.pmid: 17873172
references.citation: Oncology (Williston Park). 1996 Nov;10(11 Suppl):81-111
references.pmid: 8953597
references.citation: J Clin Oncol. 2010 Jan 1;28(1):29-34
references.pmid: 19933915
references.citation: J Thorac Oncol. 2007 Jul;2(7):603-12
references.pmid: 17607115
references.citation: Clin Lung Cancer. 2009 Nov;10(6):392-4
references.pmid: 19900855
references.citation: N Engl J Med. 2006 Sep 7;355(10):983-91
references.pmid: 16957145
references.citation: Eur Respir J. 2010 Oct;36(4):915-24
references.pmid: 20889462
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3543-51
references.pmid: 18506025
references.citation: Nature. 2007 Aug 2;448(7153):561-6
references.pmid: 17625570
references.citation: J Thorac Oncol. 2011 Feb;6(2):244-85
references.pmid: 21252716
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3552-9
references.pmid: 18506026
references.citation: N Engl J Med. 2010 Oct 28;363(18):1693-703
references.pmid: 20979469
references.citation: Diagn Cytopathol. 2002 Nov;27(5):276-81
references.pmid: 12411992
references.citation: Cancer. 2009 Nov 15;115(22):5143-54
references.pmid: 19658185
references.citation: J Thorac Oncol. 2010 Oct;5(10):1706-13
references.pmid: 20871269
references.citation: J Thorac Oncol. 2011 Sep;6(9):1601-12
references.pmid: 21849857
references.citation: J Clin Oncol. 2008 Nov 1;26(31):5043-51
references.pmid: 18809614
references.citation: Pneumologie. 2011 Jan;65(1):39-59
references.pmid: 21157688
references.citation: Int J Cancer. 2006 Aug 15;119(4):727-34
references.pmid: 16557579